P2X3 receptor antagonists

A compound according to formula I:

• or an enantiomer, diastereomer, N-oxide, or a pharmaceutically acceptable salt or combinations thereof, wherein:
• one or two of the A groups comprise nitrogen atoms, and the remaining A groups each comprises carbon atom;
• X—Y represents a N—C group;
• each R1 independently represents H, morpholinyl, oxetanyl, piperazinyl, piperidinyl, pyranyl, pyrrolidinyl, or derivative thereof,
• R2 is an optionally substituted, C1-C6 alkyl group, C1-C6 alkoxy group, C4-C14 arylalkyl group, C4-C14 heteroarylalkyl group, C3-C7 cycloalkyl group, a mono-, bi- or tricyclic C6-C14 aryl group or a mono-, bi- or tricyclic C1-C13 heterocyclic group containing from 1 to 5 heteroatoms selected from N, O or S;
• groups R3 and R4 are linked to each other to form a five-membered heterocyclic ring containing 2 or 3 nitrogen atoms or six-membered heterocyclic ring containing 2 b nitrogen atoms, substituted with one or more groups R6;
• R5 is O double-bonded directly to the X—Y containing ring;
• each R6 independently represents a halogen atom selected from F, Cl, Br or I;
• or an, optionally substituted, carbonyl, oxo, C1-C6 alkyl, C1-C6 alkoxy or C3-C7 cycloalkyl group, an, optionally substituted, mono-, bi- or tricyclic C6-C14 aryl group or an, optionally substituted, mono-, bi- or tricyclic C1-C13 heterocyclic group containing from 1 to 5 heteroatoms selected from N, O or S or alternatively, two R6 groups are linked to each other to form a group of the formula -(Zp)- wherein p is an integer of from 3 to 5 and each Z independently represents an oxygen atom or an optionally substituted methylene group, provided that no two adjacent Z moieties represent oxygen atoms;
• and
• n is an integer independently selected from 0 to 3.

A compound according to formula I:

• or an enantiomer, diastereomer, N-oxide, or a pharmaceutically acceptable salt or combinations thereof, wherein:
• one or two of the A groups comprise nitrogen atoms, and the remaining A groups each comprise a carbon atom;
• X—Y represents a N—C group;
• each R1 is selected from the group comprising 2-oxa-6-azaspiro[3.3]heptan-6-yl, 3-methoxymethylazetidin-1-yl, 3-methoxypyrrolidin-1-yl, 4-acetylpiperazin-1-yl, 4-aminopiperidin-1-yl, 4-hydroxypiperidin-1-yl, 4-hydroxypiperidin-1-yl-carbonyl, 4-methoxypiperidin-1-yl, 4-morpholinyl, dimethylaminopiperidin-1-yl, hydroxymethylpiperidin-1-yl, morpholin-4-ylcarbonyl, tetrahydro-2H-pyran-4-ylamino or tetrahydro-2H-pyran-4-ylaminocarbonyl;
• R2 is an optionally substituted, C1-C6 alkyl group, C1-C6 alkoxy group, C4-C14 arylalkyl group, C4-C14 heteroarylalkyl group, C3-C7 cycloalkyl group, a mono-, bi- or tricyclic C6-C14 aryl group or a mono-, bi- or tricyclic C1-C13 heterocyclic group containing from 1 to 5 heteroatoms selected from N, O or S;
• groups R3 and R4 are linked to each other to form a five- or six-membered b heterocyclic ring containing from 2 to 3 nitrogen heteroatoms, substituted with one or more groups R6;
• R5 is O double-bonded directly to the X—Y containing ring;
• each R6 independently represents a halogen atom selected from F, Cl, Br or I;
• or an, optionally substituted, carbonyl, oxo, C1-C6 alkyl, C1-C6 alkoxy or C3-C7 cycloalkyl group, an, optionally substituted, mono-, bi- or tricyclic C6-C14 aryl group or an, optionally substituted, mono-, bi- or tricyclic C1-C13 heterocyclic group containing from 1 to 5 heteroatoms selected from N, O or S or alternatively, two R6 groups are linked to each other to form a group of the formula -(Zp)- wherein p is an integer of from 3 to 5 and each Z independently represents an oxygen atom or an optionally substituted methylene group, provided that no two adjacent Z moieties represent oxygen atoms;
• and
• n is an integer independently selected from 0 to 3.